Honestly, you mostly don't feel the supplement working — and that is the appropriate expectation to set. The performance benefit is a few-percent shift in the late portion of high-intensity efforts. You will not feel "boosted" the way you might from caffeine or modafinil. What you will notice:

• Paresthesia within 10-30 minutes of a single dose ≥1.6 g. Tingling, "ant-walking," prickling — most prominent on the face/scalp/neck/ears/hands. Peaks at 20-60 min, fades by 60-90 min. Mediated by β-alanine activation of MrgprD-expressing cutaneous sensory afferents (Liu 2012 J Neurosci PMID 23077038; Shinohara 2004 PMID 15037633). Completely benign, no signal of nerve damage, just receptor activation. New users sometimes find it alarming; the right framing is "skin static, will pass." For users who hate the sensation, dose-splitting (≤1.6 g per dose) or sustained-release CarnoSyn-SR essentially eliminates it.

• Round-3 / late-set difference. The honest user-report pattern for fighters and grapplers running 5-min rounds or BJJ rolls of 6-10 min: by week 4-6 of loading, the "I can keep pushing in round 3" sensation appears. Not a sudden change — more like the floor of your conditioning rises. Some athletes don't notice it subjectively until they go off-supplement for a few weeks and feel themselves crash harder in late rounds.

• Lactate tolerance. Counterintuitively, β-alanine often raises peak blood lactate during max efforts (because you can keep working harder before pH forces you to stop), rather than lowering it. The Kratz 2017 judo study showed exactly this pattern. The subjective experience: "I'm cooked but I'm cooked at a higher work output than I used to be."

• No CNS effect, no mood change, no sleep impact. β-alanine doesn't cross into the CNS in meaningful concentrations (the substrate is consumed by skeletal muscle carnosine synthesis). Nootropic claims tied to brain carnosine in human supplementation are weak.

• For an MMA athlete loading pre-camp: you start dosing 8 weeks out, you tolerate the tingle for the first 2-3 weeks until your nervous system stops reading it as a novel signal, by weeks 4-6 you notice you're finishing 5-min sparring rounds with more in the tank, and by fight-camp opening you have a fully loaded carnosine pool that will persist through camp on a 2-3 g/day maintenance dose.

There is essentially no pharmacological tolerance. Muscle carnosine is a structural adaptation, not a receptor-mediated effect — there is nothing to down-regulate. Carnosine concentration is the rate-limiting variable, and it rises until substrate-saturated (around week 8-12) and stays there.

Cycling is unnecessary and probably counterproductive. Some users on r/Supplements post "I cycle β-alanine 8 weeks on / 4 weeks off" — this protocol gives up the maintenance benefit during the off-period (carnosine washes out ~2% per week) for no plausible biological gain. The closest legitimate version of a "cycle" is:

• Load 8-10 weeks → maintenance 1.2-3.2 g/day indefinitely. This is the protocol the ISSN data support.
• Pre-competition load → in-camp maintenance → off-season maintenance. Functional cycling driven by sport calendar, not pharmacology.

If you do stop: ~9 weeks back to baseline carnosine. There is no withdrawal, no rebound, no receptor recovery to engineer. You can resume loading at any point without penalty.

Paresthesia "tolerance" (the only real adaptation): Subjectively, regular users find the tingle becomes less noticeable over weeks of consistent dosing. This is nervous-system habituation to a familiar stimulus rather than pharmacological tolerance — but it makes long-term compliance easier.

Strongly synergistic:

• Creatine monohydrate (5 g/day): Different energy system (phosphocreatine/ATP regeneration vs. H⁺ buffering). Effects are additive and many studies in the combat-sport literature use both. The single most important supplement-stack pairing for an MMA athlete. No interaction concern.
• Sodium bicarbonate (0.2 g/kg, 60-90 min pre-session): Different buffer system (extracellular HCO₃⁻ vs. intracellular carnosine). Saunders 2017 meta-analysis specifically called out additive effect. Combat-sport meta-analyses report +8.6-20.3% mean power improvements with the combination over either alone. Watch GI tolerance; some athletes can't tolerate the dose without cramping.
• Caffeine (3-6 mg/kg pre-session): Independent mechanism (adenosine antagonism + CNS arousal). Standard pre-workout stacking. Be aware of the user's no-caffeine baseline — start at 100-150 mg if introducing.

Plausibly complementary:

• Citrulline malate (6-8 g pre-workout): NO pathway → vasodilation → substrate delivery. Different mechanism, possibly additive on volume-dependent strength work.
• Betaine anhydrous (2.5 g/day): Some additive data in resistance training; weaker evidence base than β-alanine itself.
• Taurine (1-3 g/day) as a hedge: Not required by human data, but cheap and safe. Some practitioners add it for theoretical transporter-competition concerns. Defensible, not necessary.

Neutral / safe co-administration:

• All of Dylan's V4-locked stack (Mg, NAC, citicoline, PS, DHA, curcumin, rhodiola, L-theanine, glycine, D3/K2, vitamin C). No interactions.
• Modafinil — no interaction (different organ system).
• Most peptides on Dylan's V5 horizon (BPC-157, TB-500, Selank, Adamax, Semax). No known interaction.

No meaningful conflicts. β-alanine has essentially no pharmacological reach beyond the carnosine-synthesis pathway.

β-alanine has a remarkably clean drug-interaction profile.

• No CYP450 substrate / inducer / inhibitor activity. β-alanine is not hepatically metabolized in a CYP-dependent way. Plasma clearance is fast (single-dose t½ ~25 min); muscle uptake via Tau-T / PAT-1 transporters drives the meaningful kinetics; renal excretion is the disposal route.
• No effect on hormonal contraceptives, anticoagulants, antiepileptics, antidepressants, antibiotics, or analgesics.
• Theoretical transporter competition with taurine and possibly other β-amino acid substrates of SLC6A6 (e.g., GABA in some tissues — not a CNS concern at oral doses). No human-clinical interactions reported.
• Renal impairment: β-alanine clears renally. Severe CKD could elevate exposure; the supplement is contraindicated in advanced renal disease less because of toxicity than because of insufficient safety data in that population.
• Pregnancy / lactation: No formal safety data. Default skip during pregnancy and breastfeeding — not because of a known signal, but because the data don't exist.

Practical reality for Dylan: β-alanine sits beside any current or planned compound on his stack with no expected interaction surface.

PGx for β-alanine is sparse and not actionable. The relevant genes are:

• CARNS1 (carnosine synthase) — polymorphisms affect baseline carnosine and possibly loading magnitude. No commercially validated test.
• CNDP2 (carnosinase-2) — degrades carnosine; variants probably modulate effective muscle concentration. Not testable in standard consumer panels.
• SLC6A6 (TauT) and SLC36A1 (PAT-1) — β-alanine / taurine transporters. Variation possibly affects uptake efficiency. Not on consumer PGx panels.
• HBB / muscle fibre composition (ACTN3, ACE I/D) — fibre-type genetics affect baseline carnosine because fast-twitch fibres store more. Dylan can infer fibre-type tendencies from 23andMe ACTN3 (R/R or R/X is fast-twitch favoured; X/X is more endurance-leaning).

The honest answer: β-alanine PGx isn't where you should be looking for tuning. Response is heterogeneous (~5-15% of users get smaller effects than the meta-analysis median) but the cost-benefit makes the default-yes decision robust. If Dylan turns out to be a low-responder by month 3 of loading, the response is to verify compliance and dosing rather than to chase a genetic explanation.

One PGx note relevant to stacking: If 23andMe (June 2026) returns a CYP2D6 poor-metabolizer phenotype, that affects modafinil and caffeine handling — not β-alanine.

For Dylan's V4 / V5: Bulk Supplements β-alanine powder, 500 g ($18-22 depending on month) covers 78 days at 6.4 g/day for the pre-camp load — a 2.5-month supply for ~$20. Use a 1.6 g scoop, dose × 4 with meals. Cheapest, simplest, no upside to paying premium pricing. If paresthesia bothers him through week 2, switch to NOW SR capsules.

Quality control: β-alanine is an unrelated-to-pharma commodity ingredient with established manufacturing standards. Counterfeits are essentially nonexistent at major Amazon-resold bulk vendors. Check Certificates of Analysis on request (Bulk Supplements and NutraBio publish them).

Baseline / before loading:

• Muscle carnosine (¹H-MRS, gastrocnemius or vastus lateralis) is the gold standard but is research-grade and not commercially accessible in most regions. Skip.
• Resting blood lactate at low workload (subjectively easy effort) — modest baseline; not a tracking target.
• Performance baseline: time-to-exhaustion test, Wingate, or sport-specific repeated-effort test (sparring rounds with HR + perceived exertion notes; 400-800 m or 1-mile run trial; rower 2,000 m).
• Subjective late-round fatigue VAS for sparring or BJJ rolling.

During loading (weeks 4 and 8):

• Repeat performance test — comparable conditions, comparable workout volume in the preceding week. Look for 2-5% improvement in capacity or total work; some athletes are larger responders.
• Subjective late-round VAS — better proxy than lab tests for fight performance.
• Paresthesia adaptation log — week 1 vs week 4 to confirm habituation.

Maintenance (every 2-3 months on chronic use):

• Repeat performance benchmark semi-annually. β-alanine effect should persist with maintenance dosing.

Safety panel (the standard V4-V5 panel covers this — no β-alanine-specific tests needed):

• ALT/AST, creatinine, eGFR, CK — no β-alanine signal expected; this is just because Dylan is on a full stack and overall hepatic/renal/muscle status matters.
• Plasma taurine — only if a user is concerned about the transporter-competition hypothesis. Not standard, not required.

No β-alanine-specific bloodwork. This is a clean supplement from a monitoring-burden perspective.